Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antisense oligonucleotide |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N07XX13
|
| gptkbp:brand |
gptkb:Tegsedi
|
| gptkbp:CASNumber |
1673727-73-4
|
| gptkbp:developedBy |
gptkb:Ionis_Pharmaceuticals
|
| gptkbp:hasMolecularFormula |
C230H309N67O127P19S19
|
| https://www.w3.org/2000/01/rdf-schema#label |
inotersen
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits transthyretin protein synthesis
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
thrombocytopenia
nephrotic syndrome |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
hereditary transthyretin-mediated amyloidosis
|
| gptkbp:bfsParent |
gptkb:hereditary_transthyretin_amyloidosis
gptkb:transthyretin_amyloidosis gptkb:Tegsedi |
| gptkbp:bfsLayer |
7
|